Table 1.

Ponatinib inhibits proliferation and signaling in AML cell lines driven by activated RTKs

IC50, nmol/L
Cell lineActivated RTK statusAssayPonatinibSorafenibSunitinib
MV4–11FLT3-ITDRTK phosphorylation0.3
Cell viability2412
Kasumi–1c-KIT (N822K)RTK phosphorylation20
Cell viability85956
KG1FGFR1OP2-FGFR1RTK phosphorylation3
Cell viability17>100>100
EOL1FIP1L1-PDGFRαRTK phosphorylation0.6
Cell viability0.50.53
RS4;11Native FLT3RTK phosphorylation
Cell viability>100>100>100

Note: Dash (–) indicates not tested. RS4;11 cells express native FLT3 and have not been reported to express activated RTKs.